Ongoing and future large, controlled studies including central consensus review, AFP at diagnosis for every patient, and INI1 immunohistochemistry or SMARCB1 genetic testing for suspected rhabdoid tumor cases would be required to confirm these findings. The gene discussed is AFP; the disease is rhabdoid tumor.